Encafeinados

Leadership · Appointments

Solomon Moshkevich becomes Natera CEO after Steve Chapman steps aside

The 15-year Natera executive takes the CEO role immediately and joins the board, while Chapman steps aside from the top job but remains an adviser and consultant.

EDThe Encafeinados Desk4 min read2 sources
Solomon Moshkevich becomes Natera CEO after Steve Chapman steps aside

Natera appointed Solomon Moshkevich chief executive and a member of its board, effective immediately, after Steve Chapman stepped down from the CEO role. Moshkevich had been president of clinical diagnostics; Chapman will remain a consultant for an extended period and an adviser to the board, according to Natera’s announcement carried by Business Wire and independent coverage from MedTech Dive.

The transition puts a 15-year company veteran in the top job. Moshkevich joined Natera in 2011 and held leadership roles across marketing, product management, medical and scientific affairs, commercial operations, clinical trials, business development, regulatory affairs and portfolio strategy. Before the CEO appointment, he led clinical diagnostics and had been the company’s first general manager of oncology.

A handoff with a long internal runway

Natera’s announcement credits Moshkevich with helping build and commercialize tests used in reproductive health, organ health and oncology, including Panorama, Prospera and Signatera. The company operates in cell-free DNA testing, where its products are used for prenatal screening, assessment of organ rejection and monitoring for cancer recurrence. Those product areas describe the scope of the business he inherits; the company did not announce a separate change to its strategy alongside the appointment.

Chapman said the timing was right and that Moshkevich had been involved in major company decisions. Executive Chairman and co-founder Matthew Rabinowitz described the promotion as the second time Natera had elevated a deeply connected internal leader to CEO. Chapman will continue as an adviser and consultant, although the release does not set an end date for either role.

MedTech Dive reported that analysts viewed the timing as unexpected and relayed their assessment that the long tenure of the new CEO could support continuity. That is analyst commentary, not a company forecast. The concrete transition is immediate: Moshkevich now leads the company, Chapman leaves the CEO seat, and the board gains the new chief executive as a member.

Readers can compare this internal succession with CooperCompanies’ recent CEO transition, another health-sector handoff in which the board clarified how the outgoing chief executive would remain connected to the business. Natera’s arrangement is different in detail, but it likewise makes the predecessor’s transition role explicit.

Go deeper

Sources

  1. 01Business Wirebusinesswire.com
  2. 02MedTech Divemedtechdive.com

Keep reading